Takeda Hosts IBD Nexus Summit 2025 in Dubai, Marking a Decade of Transformative Gastrointestinal Care
Takeda successfully hosted the IBD Nexus Summit 2025 at Sofitel Dubai the Obelisk, reinforcing its commitment to enhancing patient care for Inflammatory Bowel Disease (IBD). The two-day summit commemorated a decade of transformative care for IBD patients and aligned with the "We the UAE 2031" Vision, focusing on improving quality of life and advancing specialized treatments.
The event gathered leading gastroenterology experts, researchers, and healthcare professionals from across the region, including representatives from the Saudi Gastroenterology Association and the Emirates Gastroenterology and Hepatology Society. Discussions centered around advancing patient-centered care, enhancing disease awareness, and exploring innovative treatments for IBD management.
IBD, a chronic inflammatory condition affecting the gastrointestinal tract, has seen rising prevalence in the Middle East, impacting patients' physical and psychological well-being. The summit emphasized early diagnosis, personalized treatment solutions, and cutting-edge medical advancements to improve patient outcomes.
Speaking on the summit’s impact, Prof. Majid Al-Madi, President of the Saudi Gastroenterology Association, highlighted the event’s role in fostering collaboration and knowledge exchange among specialists, ensuring better treatment approaches for IBD patients.
Dr. Sameer Al Awadhi, President of the Emirates Gastroenterology and Hepatology Society, emphasized the importance of personalized treatment strategies tailored to individual patient needs, which are crucial for effective IBD management and improved quality of life.
Takeda’s General Manager for the West Gulf Cluster, Dr. Khaled Sary, reaffirmed the company’s dedication to advancing early detection, innovative treatments, and patient-centered care. Ahmed Fayed, General Manager for East Gulf & Levant, echoed this sentiment, stressing that global collaboration and research are vital in transforming IBD treatment.
The summit featured keynote presentations, panel discussions, and expert-led sessions on early diagnosis, emerging therapies, and advancements in gastrointestinal research.
Takeda remains at the forefront of scientific research in gastroenterology, continuously pioneering innovative therapies to enhance the standard of care for IBD patients. Through events like the IBD Nexus Summit, the company aims to drive meaningful progress in the field and empower patients to manage their condition more effectively.
